-

Forge Biologics to Present at Jefferies Virtual Healthcare Conference

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that its CEO, President and Co-Founder Timothy J. Miller, Ph.D., will present at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021. Dr. Miller will provide a company overview, detailing the company’s growth from its launch in July, 2020 with $40 million in Series A financing, to an additional $120 million Series B round in less than a year.

Jefferies Virtual Healthcare Conference—June 1-4, 2021

Date: Friday, June 4, 2021
Time: 11:30-11:55am EST
Webcast: virtual webinar link here or https://wsw.com/webcast/jeff174/forge/1996245
Webcast replay link: A replay will be accessible on the Insights page of the company website at https://insights.forgebiologics.com/

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft2 facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit www.forgebiologics.com.

Contacts

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.
Investors@forgebiologics.com

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.
medicalaffairs@forgebiologics.com

Forge Biologics


Release Summary
Forge to Present at Jefferies Healthcare Conference
Release Versions

Contacts

Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com

Investor Relations
Christina Perry
Vice President, Finance and Operations
Forge Biologics Inc.
Investors@forgebiologics.com

Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria Escolar
Chief Medical Officer
Forge Biologics Inc.
medicalaffairs@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Forge Biologics Among Select Global CDMOs to Earn My Green Lab® Certification Across All Laboratories and cGMP Suites

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced it has achieved My Green Lab® Certification, the global gold standard for laboratory sustainability best practices, across all of its laboratories and manufacturing suites. This milestone reflects a company-wide effort to embed sustainable practices across Forge’s operation, reinforcing its commitment to operational excellen...

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria

PEABODY, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for chi...

Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease

BOSTON & COLUMBUS, Ohio--(BUSINESS WIRE)--Ascidian Therapeutics (“Ascidian”), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of ACDN-01, Ascidian’s lead retinal program for the treatment of Stargardt disease. Through this collaboration, Forge is providing Asci...
Back to Newsroom